NCT06152809 2026-03-18
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Phase 1 Recruiting
Clinical Trials
9 trialsNCT06321484 2026-03-04
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06138587 2026-01-02
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05881525 2025-07-16
NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
TCRCure Biopharma Ltd.
Phase 1 Recruiting
NCT06047977 2025-07-16
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06302062 2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1 Recruiting
NCT03891706 2024-09-19
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1 Recruiting
NCT06121557 2023-11-08
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1 Recruiting
NCT06121570 2023-11-08
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1 Recruiting